Merck reorganized its human‑health operations, creating a standalone oncology business and a separate specialty, pharma and infectious‑disease unit. The move assigns Keytruda and the oncology pipeline to the new cancer unit while non‑oncology products and vaccines move to the other business. The reorganization accompanies leadership changes that place Jannie Oosthuizen over oncology and brings in Brian Foard to lead the specialty and infectious‑disease unit. Merck framed the split as sharpening commercial focus ahead of Keytruda’s expected U.S. loss of exclusivity. Investors and industry observers view the reorg as an attempt to protect oncology launch execution and clarify go‑to‑market strategies as blockbuster revenue pressure rises.